Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00311623 · ClinicalTrials.gov registry record · Phase 1
Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00311623 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 32 participants.
The verdict
NCT00311623, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying the best dose of sirolimus and to see how well it works before surgery in treating patients with advanced localized prostate cancer.
Interventions
- PROCEDURE Radical prostatectomy
- DRUG Rapamycin 3mg
- DRUG Rapamycin 6mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-08 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00311623
The ClinicalTrials.gov registry entry for NCT00311623 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radical prostatectomy is the first listed.
NCT00311623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00311623 about?
NCT00311623 is a clinical study titled "Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer". RATIONALE: Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying the best dose of sirolimus and to see how well it works before surgery in treat...
What is the current status of trial NCT00311623?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2006-08. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00311623?
The interventions under investigation include: Radical prostatectomy (PROCEDURE), Rapamycin 3mg (DRUG), Rapamycin 6mg (DRUG).
Who is sponsoring clinical trial NCT00311623?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.